A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...
Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...
Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...
Provides longer GLP-1 receptor activation. Depending on the medication, the effects can last for a minimum of 24 hours to a ...
A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...
For example, a starter dose of Novo’s Ozempic is 25 milligrams ... Hims' business has grown significantly, as have other ...
This is just a glimpse of the GLP-1 insights available to CivicScience clients. Want to see the full picture? Let’s talk.
A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...
"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...
Perrigo intends to put focus at select retailers on over-the-counter medications that relieve the side effects of GLP-1 drugs ...
Weight loss drugs like Ozempic and Wegovy may provide strong relief from severe osteoarthritis knee pain, new research finds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback